cyrilzakka/clinical-trials huggingface dataset:
Comparison of the Effectiveness of Treatments in Carbon Monoxide Intoxications

Carbon monoxide (CO) poisoning is a condition that occurs as a result of inhaling carbon monoxide gas and can potentially lead to serious health issues. The treatment of CO poisoning requires urgent medical intervention. Methods used in the treatment of CO poisoning include normobaric oxygen (oxygen at normal pressure), high-flow oxygen, non-invasive continuous positive airway pressure (CPAP), and hyperbaric oxygen therapy. Studies on these methods are available in the literature.

When examining the mechanisms of application for these methods:

Normobaric Oxygen Therapy: In normobaric oxygen therapy, researchers treat participants with normobaric (sea level) oxygen. This method provides high concentrations of oxygen, allowing better oxygen saturation of the blood and faster removal of carbon monoxide from the body. Participants inhale normobaric oxygen through devices such as masks or nasal cannulas.

High-Flow Oxygen Therapy: In high-flow oxygen therapy, researchers treat participants with high-flow oxygen. Typically, a nasal cannula or oxygen mask is used. The high flow rate allows more oxygen to reach the alveoli and bind to hemoglobin. This method can be effective, especially in more severe cases of carbon monoxide poisoning.

Non-Invasive CPAP Therapy: Non-invasive CPAP therapy is typically used to treat respiratory problems such as sleep apnea but can also be used in the treatment of CO poisoning. Participants receive oxygen under continuous positive airway pressure with the help of a mask.

Comparison of these methods:

Normobaric oxygen is considered the standard treatment for CO poisoning and generally effectively eliminates carbon monoxide from the body. High-flow oxygen may be more effective in providing additional oxygen in more severe cases, but it works similarly to normobaric oxygen. The choice of which treatment method to use can vary depending on the participant's clinical condition, the severity of poisoning, and other factors. The researchers main goal in designing this study is to determine which treatment, depending on the researcher's decision, most rapidly shortens the half-life of carbon monoxide in participants experiencing severe carbon monoxide poisoning.The researchers aim to identify which treatment participants tolerate better and which method minimizes complications related to CO intoxication.

Eligibility Criteria:
Inclusion Criteria:

* Between the ages of 18 and 65,
* Without any underlying health conditions,
* Diagnosed with carbon monoxide poisoning,
* Capable of providing consent either personally or through a legal representative.

Exclusion Criteria:

* Under the age of 18,
* Over the age of 65,
* With underlying health conditions,
* Without a diagnosis of carbon monoxide poisoning,
* Patients who do not wish to share their data.
Long Term Results and Complications After Epistaxis Treatment

The aim of this study is to find the most agreeable and in the long term most efficient treatment for epistaxis.

In the general population epistaxis occurs quite frequently. Approximately 60% of persons will be affected once in their lifetime, and 6% thereof will seek medical advice. Thereby anterior and posterior epistaxis are discerned. Anterior epistaxis is usually located at the Locus Kisselbachii, while posterior bleeds are found further back in the nose. There, most bleeds will originate from the A. sphenopalatina or the A. ethmoidalis.

Different treatment modalities exist. Anterior epistaxis are usually easier to treat than posterior ones. The aim of this study is to find the most efficient treatment. This involves the assessment of long term results and potential sequelae. Existing data will be complemented with information about recurrences and complications. The question is: Which treatment method leads to the least numbers of recurrences in the long term with the fewest long term sequelae?

Secondly, the most agreeable, least painful treatment method is to be identified. Therefore we will send out questionnaires to patients that were treated between March 29, 2007 and April 1st, 2008 at the Zurich University Hospital.

Eligibility Criteria:
Inclusion Criteria:

All patients treated during the study period with known address and who did not decease in the meantime.

Exclusion Criteria:

Insufficiently filled out questionnaires; Obvious lack of ability to remember (as tested by control questions); Known mental disability
Evaluation of Acclimate Feature for Positive Airway Pressure (PAP) Therapy

The purpose of the study is to evaluate if using the Acclimate feature at the beginning of Positive Airway Pressure (PAP) therapy results in patients using their PAP therapy at least as long as they would standard therapy. Additionally, the Acclimate feature will be evaluated with regard to patient comfort, ease of acceptance of PAP therapy, leak events, and respiratory events.

Acclimate has been designed as a comfort feature for patients starting PAP therapy. The feature allows acclimatization to the targeted positive airway pressure setting. Using the Acclimate feature, the pressure increases incrementally over a period of time. The feature can be only be used for a set period of time, afterwards which the device initiates the therapeutic session at the prescribed pressure.

Eligibility Criteria:
Inclusion Criteria:

* Subjects ≥18 years of age.
* Recent diagnosis of moderate to severe OSA where fixed PAP is clinically indicated.
* Naïve to PAP therapy.

Exclusion Criteria:

* Patients requiring supplemental oxygen.
* Patients with a history of pneumothorax, pneumomediastinum, cavities or cysts in the lung.
* Previous surgery to the brain, middle or inner ear, pituitary gland or sinuses.
* Middle ear infection or perforated ear drum.
* Ongoing sinus infection/sinusitis.
* Clinically significant epistaxis.
* Predominant central sleep apneas in the subject's PSG.
Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis

An evaluation of the long term safety of tanezumab when administered by subcutaneous injection every 8 weeks for up to 64 weeks

This study was terminated on 29 September 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.

Eligibility Criteria:
Inclusion Criteria:

* Must have participated in specific Phase 3 parent study

Exclusion Criteria:

* Failed screening for parent study, pregnant women, lactating mothers
Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

The purpose of this study was to assess the single-dose relative bioavailability study of 1 mg risperidone orally disintegrating tablets and (Risperdal M-TAB) under fed conditions.

Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr Reddy's Laboratories Ltd. and Janssen Pharmaceutica Products, LP. (Risperdal M-TAB) 1 mg Risperidone Orally Disintegrating Tablets in Healthy Adult Male Volunteers under Fed Conditions

Eligibility Criteria:
Inclusion Criteria:

Subjects were included in the study only if they met all of the following criteria:

* Healthy non-smoking (for at least 3 months) adult male volunteers, 18-45 years of age;
* Weighing at least 60 kg for males and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983);
* Medically healthy subjects with clinically normal laboratory profiles and ECGs;
* Voluntarily consent to participate in the study.

Exclusion Criteria:

Subjects were excluded from the study if there was evidence of any of the following at screening or at any time during the study:

* History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic, or psychiatric disease.
* In addition, history or presence of:
* alcoholism or drug abuse within the past year;
* hypersensitivity or idiosyncratic reaction to risperidone or benzodiazepines or other antipsychotic drugs;
* seizures;
* glaucoma or hypermetropia.
* Positive results on Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HbsAg) and Hepatitis C Virus (HCV) Tests.
* Subjects whose sitting blood pressure is less than 110/60 mm Hg at screening or 100/55 mm Hg before dosing.
* Subjects whose pulse is lower than 55 b.p.m. at screening or 50 b.p.m. prior to dosing. Subjects whose PR interval is ≥ 190 msec at screening and prior to dosing.
* Subjects whose aTe interval is \> 450 msec at screening and prior to dosing.
* Subjects with a body temperature ≥38°C before dosing.
* Subjects who have used any drugs or substances known to be strong inhibitors of CYP enzymes (formerly known as cytochrome P450 enzymes) within 10 days prior to the first dose.
* Subjects who have used any drugs or substances known to be strong inducers of CYP enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first dose.
* Subjects who have been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study.
* Subjects who, through completion of the study, would have donated in excess of: 500 mL of blood in 14 days, or 1500 mL of blood in 180 days, 2500 mL of blood in 1 year.
* Subjects who have participated in another clinical trial within 28 days prior to the first dose.
Propofol-remifentanyl Versus Dexmedetomidine in Awake Craniotomy: Impact on Electroclinical Seizure Activity

Awake craniotomy require a cooperative patient during resection neurosurgery phase. Anesthesiologist should guarantee analgesia, sedation, nausea and vomiting prevention, while maintaining normal vital parameters.

Neurosurgeon could be help by Intraoperative electrocorticography to maximise lesion resection and avoiding neurologic sequelae. Propofol and remifentanyl have been largely used. Dexmedetomidine represents an alternative. However little is known about the role of dexmedetomidine on Intraoperative electrocorticography.


Eligibility Criteria:
Inclusion Criteria:

* PATIENTS UNDERGOING AWAKE CRANIOTOMY FOR TUMOR RESECTION (EXCLUDED E.G. SURGERY OF EPILEPSIA)
* INTRAOPERATIVE MONITORING (IOM) WITH ELECTROCORTICOGRAPHY
* AWAKE-AWAKE-AWAKE TECHNIQUE

Exclusion Criteria:

* AGE \<18 YEARS OLD
* NON AWAKE-AWAKE-AWAKE TECHNIQUE
* ABSENCE OF IOM
Cranial Electrotherapy Stimulation on Anesthetics Consumption and Postoperative Pain

Cranial electrotherapy stimulation (CES) is a non-invasive intervention to treat anxiety, depression, insomnia, and pain. But clinical studies and applications of CES in relation to acute postoperative pain are few. tThe investigators investigate a double-blind, randomized controlled trial to figure out if intraoperative CES could decrease dosage of intraoperative anesthetics and patient-controlled analgesia (PCA) consumption in patients undergoing colon cancer surgery.

Cranial electrotherapy stimulation (CES) is a non-invasive and safe intervention, transmitting microcurrents of brain stimulation and releasing various neurotransmitters such as endorphin and downstream hormones to modulate autonomic nervous system, as a result, for treating anxiety, depression, insomnia, and pain.

Acute postoperative pain annoys patients receiving surgery. Once acute postoperative pain is poorly controlled, it may result in adverse acute effects (i.e., physiologic and psychologic stress), chronic effects (i.e., delayed long-term recovery and chronic pain), and, in consequence, excess length of hospitalization and extra costs. Besides, inflammatory reactions mediated by immune system are formed after tissue injury (e.g. trauma, surgery, etc), release serial inflammatory cytokines and are related to pain signal transmission. However, clinical studies and applications of CES focus on management of chronic pain, modulation of mood and insomnia rather than acute postoperative pain in recent years.

The investigators investigate a double-blind, randomized controlled trial to figure out if intraoperative CES could decrease dosage of intraoperative anesthetics and patient-controlled analgesia (PCA) consumption in patients undergoing colon cancer surgery. The investigators also collect blood samples before and after surgery for analysis of serum cytokines. Meanwhile, Bispectral IndexTM (BISTM) monitoring and Analgesia Nociception Index (ANI) are prescribed during the surgery not only for measuring of the effects of anesthetics and sedatives on the brain, but also evaluating perioperative analgesia. Thereby, the effectiveness of CES for management of acute postoperative pain may introduce clinicians for alternative application of pain control after surgery in the future.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing colon cancer surgery

Exclusion Criteria:

* presence of an implantable device (e.g., pacemaker)
* pregnancy
* having a known mental illness (e.g., schizophrenia, mood disorder, bipolar disorder, etc.
* cancer of the head and neck or brain tumor or brain metastasis
* having delirium
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days in anemic subjects with end-stage renal disease (ESRD) receiving hemodialysis.


Eligibility Criteria:
Inclusion Criteria:

* Subjects who have ESRD and have been receiving maintenance hemodialysis for at least 12 weeks prior to the Screening Visit
* Body weight (post-dialysis weight) greater than 45.0 kg and a body mass index between 20.0 and 40.0 kg/m2 (inclusive) at the Screening Visit
* Hemoglobin value as defined in the protocol
* Meet the erythropoiesis-stimulating agent (ESA) therapy criteria at the Screening Visit as defined in the protocol

Exclusion Criteria:

* Transferrin saturation and ferritin levels at the Screening Visit as defined in the protocol
* Anemia due to known causes other than chronic kidney disease
* Known history of hyporesponsiveness to ESAs
* Acute coronary syndrome (e.g., myocardial infarction) within 1 year prior to Screening visit
Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis

The purpose of this study is to find out whether the High Frequency Digit Triplet test can be used to screen patients with cystic fibrosis for hearing loss in conditions of health and pulmonary exacerbation. It is also designed to find out the youngest age at which a child can perform the test, the prevalence of hearing loss in a CF population and the prevalence of genetic mutations known to be associated with hearing loss in the same population.

Patients will be identified from the clinic list of four Cystic Fibrosis centres (Nottingham University Hospitals NHS (National Health Service) Trust, adults and children, West Midlands Adult Cystic Fibrosis Centre and Birmingham Children's Hospital).

In the first work stream patients 11 years old and over will answer some hearing screening questions and an ear examination and tympanogram. They will then have the new test (the High Frequency Digit Triplet, HFDT, test), the standard tests (Pure tone audiogram (PTA) including high frequencies, Distortion Product Otoacoustic Emissions) and then repeat the new test to look for order effect. These will be compared to validate the HFDT as a screening tool for hearing loss.

In the second work stream the investigators are looking to see if the test is feasible when a patient is unwell and about to start a course of IV antibiotics. The patients will have the same tests as in work stream 1 (though the high-frequency PTA may be modified if they are too unwell to complete it). They will then have the tests repeated at the next clinic visit (approximately 6-8 weeks later).

In the third work stream children aged 5-10 years will have the same tests. This is to discover the youngest age at which the HFDT test can reliably be performed. To ensure that the CF condition does not itself affect the ability to perform the test the investigators will compare CF children to healthy control children the same age.

The investigators will take blood and saliva samples from CF patients to look for mutations in mitochondrial genes which are known to be associated with aminoglycoside induced hearing loss.

Eligibility Criteria:
Inclusion criteria

Work stream 1

* A diagnosis of CF, confirmed by genotype or sweat test, with characteristic clinical features.
* Aged 11 years and over.
* Informed consent. For age 11 to 18 years, consent will be sought from both the parent and young person (provided the young person is competent).

Work stream 2

• As above but the participant has a pulmonary exacerbation (as defined by Fuch's criteria) requiring intravenous antibiotics.

Work stream 3

* As for work stream 1, defined above.
* CF patients aged 5-10 years
* Healthy control children aged 5-10 years.
* Informed consent from parent with assent from the child.

Genetic Testing

* Informed consent
* Diagnosis of CF as above

Exclusion criteria

* None. In individuals with a hearing aid, we will perform PTA and HFDT tests without the aid.
* Individuals found to have conductive deafness after randomisation will be fully assessed for this prior to continuing with the study.
DPP-4 Inhibition, Incretins and Islet Function

Hypothesis is that DPP-4 inhibition affects glucose levels through changes in incretin and islet hormones. The study examines this in relation to breakfast, lunch and dinner over an entire 24h study period by the use of three different DPP-4 inhibitors and placebo.

The study is a single-center study with a cross-over design to examine glycemia, incretin hormones and islet hormones over a 24h study period with standardized breakfast, lunch and dinner after administration of placebo, saxagliptin, vildagliptin or sitagliptin.

Eligibility Criteria:
Inclusion Criteria:

* • Caucasian men or women with type 2 diabetes diagnosed according to ICD10 at time of inclusion

  * Ongoing treatment with life style adjustment including diet and exercise regimen together with metformin as oral antidiabetic . Metformin therapy should be stable the last three months
  * Age 40-75 years
  * HbA1c 52-80 mmol/mol (inclusive)
  * BMI: 20-40 kg/m2
  * Written informed consent has been given
  * Capability and willingness to participate in the whole study

Exclusion Criteria:

* • Liver disease (K70-77 in ICD10) or liver enzymes three times above upper reference range

  * Diabetic nephropathy (GFR \< 30 mL/min/1.73 m2 or albuminuria) or other causes of renal disease
  * Proliferative diabetic retinopathy
  * Treatment with any glucose-lowering medication except metformin
  * Previous myocardial infarction, coronary heart disease or instable angina pectoris in the last 6 months.
  * Symptomatic heart failure (NYHA class II-III)
  * Previous surgery on the gastrointestinal tract
  * Larger surgical intervention during the last 12 weeks
  * Female subject who are pregnant or breast feeding
  * Women of child bearing potential not using a highly effective method of birth control
  * Treatment with oral steroids, thiazide diuretics, digoxin or growth hormone
  * Hypersensitivity to the active substances of to any of the excipients
  * Participation in another study the last 4 weeks
  * Smoker
  * Paracetamol intolerance
Cardiovascular and Psychological Consequences of COVID-19

The study will assess cardiac and psychological profile at 2-3 months after recovery from COVID-19 infection.

A significant proportion of patients hospitalized for COVID-19 showed laboratory signs of myocardial damage, detected by elevated troponin levels, and these were associated with more severe clinical course and higher mortality. Moreover, it is unknown how the health emergency and the associated conditions may have influenced and still influence the psychological experience of the affected people.

Thus, in order to promote continuity of care, post-COVID-19 disease clinics have therefore been activated dedicated to a specific follow-up program for monitoring long-term alterations and for the early identification of patients requiring rehabilitation.

The program includes a first follow-up visit (2-3 months after recovery) including cardiac (2D-echocardiography, six-minute walking test, autonomic function evaluation) and psychological (Patient Health Questionnaire-9 (PHQ-9) Generalized Anxiety Disorder-7 (GAD) National Stressful Events Survey PTSD Short Scale (NSESSS)) evaluation.

A second follow-up visit will be performed at 12 months in the form of structured interview,

Eligibility Criteria:
Inclusion Criteria:

* Recent discharge (≤ 3 months) from a COVID+ ward for SARS-CoV-2 disease

Exclusion Criteria:

* Serious clinical conditions (severe chronic inflammatory diseases, neoplasms, neurological pathologies).
* Non-Italian education, illiteracy, or return to illiteracy.
* Severe visual-perceptual deficits.
* Low motivation/interest or refusal to undergo the assessment.
Comparison of Dual-Task Timed Up and Go Test (Cognitive) and 3-m Backwards Walk Test

Two balance assessment tools that have been used recently have attracted considerable attention: the Dual-Task Timed Up and Go Test (cognitive) (DTUG) and the 3-m Backward Walk Test (3MBWT). The aim of this study is to compare the psychometric properties of two clinically proven balance assessment tools.

There are unidimensional and multidimensional scales used to evaluate gait balance after stroke. Unidimensional scales (DTUG, 3MBWT) can be useful in clinical practice and in screening for basic balance problems. Two balance assessment tools that have been used recently have attracted considerable attention: the Dual-Task Timed Up and Go Test (cognitive) (DTUG) and the 3-m Backward Walk Test (3MBWT). The aim of this study is to compare the psychometric properties of two clinically proven balance assessment tools. In the study, construct validity, concurrent validity, reliability, and cut-off score (for determining falling risk) of the two tests will be calculated.

Eligibility Criteria:
Inclusion Criteria:

* Single stroke with unilateral hemiparesis at least 6 months prior to the study,
* Be in the age range of 50-85 years
* Able to walk at least 10 meters independently with or without a walking aid,
* Getting at least 24 points from the Standardized Mini-Mental Test
* It is to be able to follow two-stage commands and perform subtraction.

Exclusion Criteria:

* Presence of additional orthopedic or neurological diseases that may affect balance and walking,
* Having uncorrected vision and hearing problems
Postoperative Effects of Chewing Gum, Ibuprofen and Acetaminophen on Pain After Initial Archwire Placement

The purpose of this study is to compare the efficacy of ibuprofen, acetaminophen, chewing gum in reducing orthodontic pain. This study include 81 patients to be classified into 4 groups of 19 each: ibuprofen (400 mg), acetaminophen (500 mg), chewing gum and control. The patients in each group will receive 1 method immediately after placement of the initial archwire and every 6 hours for a week if they experiences pain. Pain perception will be recorded by the patients while jaw rest position and fitting back teeth at 2 hours, 24 hours, 2 days, 3 days, 7 days and 21 days after archwire placement, using a visual analog scale.


Eligibility Criteria:
Inclusion Criteria:

* moderate teeth crowding
* no need for tooth extraction to orthodontic reasons

Exclusion Criteria:

* presence of autoimmune diseases
* history of orthodontic treatment with fixed appliances